<DOC>
	<DOCNO>NCT00370851</DOCNO>
	<brief_summary>In study intend evaluate outcome intravitreal avastin improve visual acuity macular edema late complication BRVO like NVD NVE</brief_summary>
	<brief_title>Intravitreal Bevasizumab VS Sham Treatment Acute BRVO : A Randomized Clinical Trial</brief_title>
	<detailed_description>After diabetic retinopathy , vein occlusion second common retinovascular disease . According BVO study effective management macular photocoagulation macular thicken persist 3 months.But may miss golden time result photoreceptor degeneration due macular edema period . VEGF inhibitor newly show may effective wide range retinovascular disease result macular edema new vessel formation . In study aim show outcomes one VEGF inhibitor ( bevacizumab ) complication BRVO sham control clinical trial .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>patient acute BRVO le three month duration vision le 20/320 vison 20/50 duration 3 month history glaucoma diabetic retinopathy medium opacity prevent funduscopy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>intravitreal Avastin</keyword>
	<keyword>BRVO</keyword>
	<keyword>Macular edema</keyword>
</DOC>